Abstracts tagged "treatment"

Abstract Number: 948 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Alan J. Kivitz¹, Anna Zubrzycka-Sienkiewicz², Sergio R. Gutierrez-Ureña³, Jeffrey Poiley⁴, Rita Kristy⁵, Kathyjo Shay⁵ and Jay P. Garg⁵, ¹Altoona Center for Clinical Research, Duncansville, PA, ²ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, ³Hospital Civil de Guadalajara FAA, CUCS UdG, Guadalajara, Mexico, ⁴Arthritis Associates, Orlando, FL, ⁵Astellas Pharma Global Development, Northbrook, IL
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…
Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
V. Strand¹, R. Riese², R. Gerber², D. Gruben², A.G. Bushmakin², E.Y. Mahgoub³ and G. Wallenstein², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…
Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting
Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
R. van Vollenhoven¹, Y. Tanaka², R. Riese³, M. Lamba³, T. Kawabata³, T. Hirose⁴, S. Toyoizumi⁴, A. Hazra³ and S. Krishnaswami³, ¹The Karolinska Institute, Stockholm, Sweden, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting
First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Tristan Pascart¹, Rene-Marc Flipo², Xavier Deprez³ and Eric Houvenagel⁴, ¹Rheumatology, Saint-Philibert Hospital, Lille, France, ²Rheumatology, University Hospital Lille, Lille, France, ³Rhumatologie, Ch De Valenciennes, Valenciennes, France, ⁴Rheumatology, Saint-Philibert Hospital, LOMME, France
Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
Abstract Number: 2428 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Rheumatoid Arthritis Disease Activity Indices in Two Populations of Meteor Database
Helena Canhão¹, Fernando Magalhaes Martins², Jose Antonio Melo Gomes³, Maria Jose Santos⁴, Augusto Faustino⁵, José Antonio Costa⁶, Cornelia Allaart⁷, E. Gvozdenovic⁸, Pedro Machado⁹, Jaime C. Branco¹⁰, João E. Fonseca¹¹ and José Pereira Da-Silva¹², ¹Av. Prof. Egas Moniz, Hospital Santa Maria, Lisboa, Portugal, ²Portuguese Society of Rheumatology, Lisbon, Portugal, ³Instituto Português de Reumatologia, Lisbon, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Clínica de Reumatologia de Lisboa, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ⁷Rheumatology, Leiden Univ Med Ctr, Leiden, Netherlands, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁰Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹¹Lisbon Academic Medical Center, Lisbon, Portugal, ¹²Rheumatology, Hospitais da Universidade de Coimbra, Coimbra, Portugal
Background/Purpose Our aims were to assess disease activity states using DAS28ESR, CDAI and SDAI and to compare their outcomes in two rheumatoid arthritis (RA) populations…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 2395 • 2014 ACR/ARHP Annual Meeting
Understanding Patient Preferences Associated with the Use of Therapies for Rheumatoid Arthritis: Results of a Conjoint Analysis
K. Saverno¹, A. Louder¹, A. Singh², J. Cappelleri³, A. Aten⁴, A. Koenig⁵ and M. Pasquale¹, ¹Comprehensive Health Insights Inc, Louisville, KY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY, ⁴Humana Inc, Louisville, KY, ⁵Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib provides patients with a new oral alternative to biologic…
Abstract Number: 378 • 2014 ACR/ARHP Annual Meeting
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate
Gerd Burmester¹, Gurjit S. Kaeley², Jeffrey R. Curtis³, Yusuf Yazici⁴, Benoit Guerette⁵, Xin Wang⁵, Alan Friedman⁵ and Vibeke Strand⁶, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²College of Medicine, University of Florida, Jacksonville, FL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵AbbVie, Inc., North Chicago, IL, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose The prediction of treatment outcomes based on early response could guide treatment decisions in patients (pts) with rheumatoid arthritis (RA). The objective was to…
Abstract Number: 2406 • 2014 ACR/ARHP Annual Meeting
Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², J. Bourret³ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Injectable biologics are commonly used to treat patients (pts) with moderate to severe rheumatoid arthritis (RA); the frequency with which they are prescribed but…
Abstract Number: 100 • 2014 ACR/ARHP Annual Meeting
Evaluation of Real World Experience with Non-Biologic DMARD in the Treatment of RA: Data from an Electronic Health Record Database
D. Wiederkehr¹, J. Harnett¹, R. Gerber², D. Gruben², E.Y. Mahgoub³, G. Wallenstein¹ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Non-biologic (NB) disease-modifying antirheumatic drugs (DMARD) such as methotrexate (MTX) are commonly used to treat rheumatoid arthritis (RA). However, NB‑DMARD can have adverse events…
Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting
ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
V. Strand¹, D. van der Heijde², C. a. F. Zerbini³, C. A. Connell⁴, D. Gruben⁴, R. Riese⁴ and G. Wallenstein⁴, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
Abstract Number: 1391 • 2013 ACR/ARHP Annual Meeting
Transporters As Drug Gateway Into The Cell For Specific Targeting Of Tyrosine Kinase Signaling Pathway In Rheumatoid Arthritis
Saliha Harrach¹, Christian Schmidt-Lauber², Bayram Edemir³, Eberhard Schlatter¹, Thomas Pap⁴, Giuliano Ciarimboli¹ and Jessica Bertrand², ¹Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Münster, Germany, ²Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Münster, Münster, Germany, ³Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Muenster, Germany, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Tyrosine kinase inhibitors (TKI) are effective in treating malignant disorders and were suggested to also have an impact on non-malignant diseases such as rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.